Heron Therapeutics, Inc. (HRTX): EBITDA
-$224.0K
Year ended 2025-12-31
-$8.73M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$224.0K | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$9.04M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$107.72M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$171.77M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$214.81M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$225.32M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$208.65M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$182.42M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$193.03M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$169.82M | n/m | 2019-02-22, From 2016-01-01 |
| 2015-12-31 | -$96.19M | n/m | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | -$73.98M | n/m | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | -$54.12M | n/m | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | -$23.63M | n/m | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | -$10.88M | n/m | 2014-03-07, From 2011-01-01 |
| 2010-12-31 | -$9.71M | n/m | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | -$9.89M | n/a | 2012-03-26, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$49.85M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$65.67M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $50.18M | +141.0% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.35M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$9.09M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$9.22M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$191.52M | n/m |
Compare HRTX, LQDA, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗